BioSpace News Archive

Drug Development

Alzamend Neuro Receives FDA “Study May Proceed” Letter for Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type

Alzamend Neuro, Inc. today announced receipt of a “Study May Proceed” letter from the U.S. Food and Drug Administration (“FDA”) for a phase I/IIA clinical trial under its Investigational New Drug (“IND”) application for an immunotherapy (ALZN002) to treat mild to moderate dementia of the Alzheimer’s type.

October 31, 2022
·
6 min read
Loulou Foundation announces First-Patient-In for CANDID observational study on CDKL5 Deficiency Disorder

The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today that the first patient has been enrolled in the three-year observational study with CDD patients, the Clinical Assessment of Neuro Developmental measures.

October 31, 2022
·
5 min read
Business

Siemens Healthineers and University of Miami Health System Enter Value Partnership Agreement to Transform Healthcare

Siemens Healthineers and UHealth - University of Miami Health System announced a Value Partnership1 agreement.

October 31, 2022
·
3 min read
Business

Ortho Dermatologics Announces U.S. Launch of the Podiatry Board Review Challenge

Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics, recently announced the launch of the Podiatry Board Review Challenge, a new professional educational resource.

October 31, 2022
·
5 min read
Biotech Bay

Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform

Mosaic ImmunoEngineering, Inc. announced that two research grants totaling $4.3 million from the National Cancer Institute were awarded to the Company’s collaborating scientists and their respective academic institutions.

October 31, 2022
·
6 min read
Business

Sonnet BioTherapeutics Announces an Agreement with Janssen for the Evaluation of Three Sonnet Product Candidates

Sonnet BioTherapeutics Holdings, Inc. announced today a collaboration agreement with Janssen Biotech, Inc.

October 31, 2022
·
3 min read
Biotech Beach

Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

Ensysce Biosciences Inc. today announced positive topline results from a human abuse potential (HAP) study for PF614. PF614 is a new class of analgesia, a Trypsin Activated Abuse-Protected oxycodone product.

October 31, 2022
·
5 min read
Drug Development

Ainos Pursues Licensing Partners to Accelerate Five Candidates of its Low-dose Oral Interferon Formulation VELDONA to Phase 3 Trials and Commercialization

Ainos, Inc. today announced that it is pursuing out-licensing opportunities for five new drug candidates for its low-dose oral interferon-alpha (“IFNα”) formulation, VELDONA®.

October 31, 2022
·
8 min read
Business

UPDATE: Mosaic ImmunoEngineering’s Academic Collaborators Awarded Grants Totaling $4.3 Million from NCI Focused on the Company’s Novel Immuno-Oncology Platform

Mosaic ImmunoEngineering today announced that two research grants totaling $4.3 million from the National Cancer Institute (NCI) were awarded to the Company’s collaborating scientists and their respective academic institutions.

October 31, 2022
·
6 min read
Pharm Country

Glenmark Pharmaceuticals launches Fingolimod Capsules, 0.5 mg in the US

Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce it has launched their Fingolimod Capsules, 0.5 mg, the generic version of Gilenya ®1 Capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation.

October 31, 2022
·
2 min read